General Biotechnology

Two clocks. One drug. And a deadline that can’t be negotiated.
In pharma, timelines aren’t just operational—they’re strategic. The difference between “we still have protection” and “competition is at the door” can come down to two clocks running at t…

Small Molecules vs. Biologics: The Real LEO Playbook for Generics and Biosimilars
The patent landscape isn’t just “more patents” or “fewer patents.” It’s different games—and the rules change depending on whether you’re defending a small-molecule franch…

Biopharma’s next revenue window isn’t in the lab—it’s in the tender.
Drug patent cliffs are no longer a distant threat. They’re a calendar event. And for commercial vendors in Europe—especially those supporting biosimilars, generics, and off-patent l…

Pharma’s biggest “new drug” play isn’t a new molecule—it’s a new claim.
For years, investors and executives have chased the next blockbuster compound. But a quieter engine has been quietly printing billions: taking an old molecule—one that’s already be…

Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When a drug loses exclusivity, the market doesn’t simply open. It floods. Generics arrive faster than many commercial teams can retool…

One-shot: How to pick the right drug patent for maximum term-extension value
In pharma, timing is everything—but so is which clock you’re trying to extend.
Drug patent term extensions (and related exclusivity add-ons) can represent real, measurable val…

Drug patent litigation isn’t just about the molecule—it’s about the design choices around it.
In the last decade, “design-around” has evolved from a legal strategy into a core product-development discipline. And nowhere is that more true than in the …

Pharma has a $300 billion question it can’t afford to misread: is it getting a patent “term restoration” or a patent “term adjustment”?
On paper, the difference sounds technical. In practice, it can determine whether a blockbuster’s exclusivity window …

Pharma executives don’t lose in court—they lose in the calendar.
If you operate in Eurasia, the real risk isn’t just unfamiliar regulators or complex filings. It’s timing: when patents are published, when exclusivities attach, when enforcement become…

Pharmaceutical patent strategy is often treated like a binary choice: fight every case, or give up and move on. But the real world is messier—and more expensive.
In a recent piece from DrugPatentWatch, the “cut, keep, or cash” decision matrix reframes …